> Detailanzeige

Blum, William; Mrózek, Krzysztof; Ruppert, Amy S.; Carroll, Andrew J.; Rao, Kathleen W.; Pettenati, Mark J.; Anastasi, John; Larson, Richard A.; Bloomfield, Clara D.

Adult de novo acute myeloid leukemia with t(6;11)(q27;q23) : Results from Cancer and Leukemia Group B study 8461 and review of the literature

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Adult de novo acute myeloid leukemia with t(6;11)(q27;q23) : Results from Cancer and Leukemia Group B study 8461 and review of the literature : Results from Cancer and Leukemia Group B study 8461 and review of the literature
  • Beteiligte: Blum, William; Mrózek, Krzysztof; Ruppert, Amy S.; Carroll, Andrew J.; Rao, Kathleen W.; Pettenati, Mark J.; Anastasi, John; Larson, Richard A.; Bloomfield, Clara D.
  • Erschienen: Wiley, 2004
  • Erschienen in: Cancer
  • Sprache: Englisch
  • DOI: 10.1002/cncr.20489
  • ISSN: 0008-543X; 1097-0142
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>BACKGROUND</jats:title><jats:p>Acute myeloid leukemia (AML) with t(6;11)(q27;q23) is a well established but rare entity, and few studies have reported the full clinical, hematologic, and outcome data of patients with this disease.</jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p>To characterize the features of t(6;11) AML, the authors searched the Cancer and Leukemia Group B (CALGB) cytogenetic database comprising 2667 adults with newly diagnosed, de novo AML and identified 16 patients (0.6%) with t(6;11). A review of the literature identified 33 adults with de novo t(6;11) AML for whom survival data were available.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>CALGB patients had a median age of 45 years (range, 22–65 years) and commonly presented with French–American–British (FAB) subtype M4 or M5 (81%). Gingival involvement at presentation was common (31%). All patients with gingival involvement had FAB M4. Compared with other patients with M4 AML in the CALGB database (<jats:italic>n</jats:italic> = 429), patients with M4 and t(6;11) (<jats:italic>n</jats:italic> = 7) had a higher frequency of gingival hypertrophy at presentation (71% vs. 17%, <jats:italic>P</jats:italic> = 0.003). Patients with t(6;11) were more likely to be African American (<jats:italic>P</jats:italic> = 0.02) and to die during induction (<jats:italic>P</jats:italic> = 0.03) than those without t(6;11). The complete response (CR) rate was 69% (11 of 16 patients), and CR duration was short (median, 9 months). The estimated probability of 2‐year survival was 13%. Both long‐term survivors received allogeneic stem cell transplantation. The estimated probability of 2‐year survival of patients reported in the literature was 15%.</jats:p></jats:sec><jats:sec><jats:title>CONCLUSIONS</jats:title><jats:p>Although the patient sample was small, the authors suggested that investigational approaches, including allogeneic transplantation, be considered for adults with t(6;11) AML. Cancer 2004. © 2004 American Cancer Society.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang